Saxenda and Wegovy are both GLP-1 medications licensed for weight management in the UK, both manufactured by Novo Nordisk. Wegovy (semaglutide) is typically more effective than Saxenda (liraglutide) for weight loss, requires weekly rather than daily injections, and has become the second-line alternative to Mounjaro for most UK users. Saxenda is still used in specific clinical contexts. This is the honest UK comparison, including who should consider each.
For the wider picture see Tirzepatide vs Semaglutide UK. For how to access these medications: How to Get Mounjaro in the UK.
Quick summary table
| Feature | Saxenda | Wegovy |
|---|---|---|
| Active ingredient | Liraglutide | Semaglutide |
| Manufacturer | Novo Nordisk | Novo Nordisk |
| Injection frequency | Daily | Weekly |
| UK licensing (weight) | 2015 | 2023 |
| Typical weight loss at 68-72 weeks | 5–8% | 12–15% |
| Maintenance dose | 3mg daily | 2.4mg weekly |
| Typical UK private cost | £150–£250/month | £200–£350/month |
| NHS availability | Limited (ended in 2024 for most pathways) | Limited, tier-4 services only |
The mechanism
Both Saxenda and Wegovy are GLP-1 receptor agonists — they activate the GLP-1 receptor in your brain and gut, producing:
- Increased feelings of fullness
- Slowed gastric emptying
- Reduced appetite
- Improved glycaemic regulation
- Reduced food noise/cravings (less pronounced than with Mounjaro, but present)
The differences between them are about pharmacokinetics (how long they stay active in the body) and receptor binding affinity. Wegovy’s semaglutide has a longer half-life (allowing weekly dosing) and stronger receptor activation at therapeutic doses.
Saxenda (liraglutide)
The short version
Saxenda was the first GLP-1 medication licensed specifically for weight management in the UK, back in 2015. It requires daily injection, produces modest weight loss (5–8% at 68 weeks in clinical trials), and is now rarely chosen as first-line treatment given the availability of Wegovy and Mounjaro.
Dose schedule
- Week 1: 0.6mg daily
- Week 2: 1.2mg daily
- Week 3: 1.8mg daily
- Week 4: 2.4mg daily
- Week 5 onwards: 3mg daily (maintenance)
Strengths
- Longest track record (10+ years in UK market)
- Well-understood side effect profile
- Daily dosing means missed doses are only minor disruption (missing 1 of 7 is less impactful than missing 1 of 1)
- Can be useful in specific clinical contexts (e.g., patients who can’t tolerate semaglutide/tirzepatide)
Weaknesses
- Daily injection burden (7 injections per week vs 1 for weekly alternatives)
- Lower average weight loss than Wegovy or Mounjaro
- Higher total injection-site exposure (more bruising, rotation complexity)
- Cost per kilogram lost is generally less favourable than weekly medications
Who might choose Saxenda
- Users who specifically can’t tolerate weekly dosing pharmacokinetics (some people do better with daily medication steadier state)
- Users who’ve had issues with semaglutide or tirzepatide and need an alternative
- Users in NHS pathways where Saxenda is still available and Wegovy/Mounjaro aren’t
- Short-term use while waiting for other medication access
Wegovy (semaglutide)
The short version
Wegovy is the weight-management formulation of semaglutide, the same drug as Ozempic (diabetes brand). Weekly injection, significantly more effective than Saxenda, approved in the UK in 2023. Second-most-prescribed GLP-1 after Mounjaro.
Dose schedule
- Week 1–4: 0.25mg weekly
- Week 5–8: 0.5mg weekly
- Week 9–12: 1mg weekly
- Week 13–16: 1.7mg weekly
- Week 17 onwards: 2.4mg weekly (maintenance)
Strengths
- Effective weight loss (12–15% at 68 weeks in STEP trials)
- Weekly dosing reduces injection burden
- Same active ingredient as Ozempic (well-established diabetes medication)
- Strong data for cardiovascular benefit in overweight adults with existing cardiovascular disease
- Widely available at UK private providers
Weaknesses
- Slightly less effective than Mounjaro (12–15% vs 15–22% weight loss)
- Side effect profile similar to Saxenda (nausea, constipation, reflux common)
- Can cause pronounced “food noise reduction” that some users find disorienting
- Supply has been constrained at various UK points in 2024–2026
Who might choose Wegovy
- First-line for users who don’t have access to Mounjaro or who specifically prefer semaglutide
- Users with cardiovascular comorbidities (stronger cardiovascular trial data vs tirzepatide, though this is evolving)
- Users who experienced intolerable side effects on tirzepatide but want to try another GLP-1
- Cost-sensitive users where Wegovy provider pricing is slightly lower than Mounjaro at their chosen provider
Head-to-head comparison points
Weight loss efficacy
- Saxenda trials: average 5–8% weight loss at 68 weeks
- Wegovy (STEP trials): average 12–15% weight loss at 68 weeks
- Both: individual results vary widely; 20%+ weight loss is achievable on Wegovy, rare on Saxenda
Wegovy wins clearly on weight loss efficacy for the average user.
Side effect profile
Both medications share the GLP-1 side effect profile:
- Nausea (most common, particularly during titration)
- Constipation
- Diarrhoea (less common than constipation)
- Reflux / heartburn
- Injection-site reactions
- Rare: pancreatitis, gallbladder issues
Head-to-head, side effect profiles are broadly similar. Saxenda’s daily dosing means side effects tend to be lower-intensity but more continuous; Wegovy’s weekly dosing means side effects cluster in 1–3 days post-injection but are fuller-intensity.
Convenience
Wegovy’s weekly dosing is clearly more convenient than Saxenda’s daily injection. Over a year, that’s 52 injections vs 365. Significant quality-of-life difference.
Cost
Both medications have similar total monthly costs in the UK private market (£150–£350 depending on provider, dose, and subscription vs monthly). Saxenda’s lower average cost is partially offset by requiring daily dosing which means more total doses per month for some buyers.
Cardiovascular data
Wegovy has the SELECT trial showing cardiovascular benefit in overweight adults with existing cardiovascular disease. This is clinically meaningful for specific patient populations. Saxenda has some cardiovascular data but less definitive.
Tirzepatide’s cardiovascular trials are ongoing and maturing; early data is promising but less definitive than Wegovy’s.
Diabetes overlap
If you have type 2 diabetes alongside overweight/obesity:
- Saxenda for weight management + Victoza (same drug) for diabetes = redundant
- Wegovy for weight management + Ozempic (same drug) for diabetes = also redundant; typically one prescription covers both needs
- Mounjaro for either indication — works well for both
Prescribers consider which branded product is appropriate based on your specific clinical picture.
NHS access in 2026
Rough state of NHS availability (verify with your GP for current status):
Saxenda on NHS: historically available through tier-3 and tier-4 weight management services; widely discontinued from most NHS weight management pathways during 2024 as more effective alternatives took precedence. Still used in specific clinical contexts.
Wegovy on NHS: limited availability; approved in some tier-3 and tier-4 specialist services for specific eligible patients (typically BMI 35+ with significant comorbidity). Rollout has been slower than public interest.
Mounjaro on NHS: Cohort 1 rollout for high-risk patients ongoing from 2024, with expansion planned; most users requiring GLP-1 treatment still access via private pathways.
Private prescribing is the practical route for most UK adults seeking any of these medications.
Switching between Saxenda and Wegovy
Moving between GLP-1 medications is generally straightforward:
Saxenda to Wegovy:
- Stop daily Saxenda injections
- Wait ~48 hours after last Saxenda dose
- Start Wegovy at the lowest dose (0.25mg weekly)
- Titrate up per standard schedule
- Expect some adjustment in first 2–4 weeks; new side effect pattern (weekly peaks vs daily steady-state)
Wegovy to Saxenda (less common direction):
- Usually initiated when Wegovy isn’t tolerated or available
- Wait 1–2 weeks after last Wegovy dose
- Start Saxenda at 0.6mg daily; titrate to maintenance
Switching between medications should be done with prescriber oversight, not self-initiated.
Common questions
“Is Saxenda completely obsolete now?” Not completely. It still has a role for users who can’t tolerate weekly medications, who need shorter-acting GLP-1 activity for specific clinical reasons, or who are bridging gaps in supply of other medications. But it’s rarely first choice in 2026.
“Is it safe to switch between GLP-1 medications?” Yes, with prescriber oversight and a short washout period. Your prescriber will guide timing and starting dose on the new medication. Self-switching is not advisable because dose equivalencies aren’t intuitive (2.4mg Wegovy is not “the same strength” as 3mg Saxenda despite being numerically larger).
“Why did Saxenda fall out of favour so quickly?” Two things: first, Wegovy arrived with better efficacy data and weekly dosing. Second, the UK market’s gradual shift toward Mounjaro as the dominant GLP-1 has relegated both Wegovy and Saxenda to second- and third-line. Saxenda’s daily dosing was always its biggest practical friction point; newer alternatives removed that friction.
“Could I start with Saxenda as a ‘trial’ to see how I tolerate GLP-1s?” Clinically possible but rarely chosen. If you’re considering GLP-1 treatment and are concerned about tolerance, starting Wegovy or Mounjaro at their lowest titration dose gives similar “test” information with better access to a long-term medication if it works for you. A short Saxenda trial followed by switching costs more and takes longer than starting with a weekly medication at a low dose.
“Is the daily injection with Saxenda really that bad?” For some, not at all. For many, it’s a meaningful quality-of-life difference over 12+ months. 365 injections a year vs 52 is a real gap. Injection fatigue is underappreciated until you’ve experienced it.
“Does Saxenda work faster because it’s daily?” No. Both medications take weeks to show full effect. Daily dosing reaches steady-state faster pharmacokinetically (within 2–3 days rather than 4–5 weeks), but the clinical appetite-suppression effect takes similar time to develop on both.
“Why does NHS coverage differ between these drugs?” NICE (National Institute for Health and Care Excellence) reviews each medication separately and makes cost-effectiveness recommendations. Different review timelines, different clinical priority assessments, and different price negotiations result in different NHS pathways for different GLP-1s.
The bigger question: Saxenda, Wegovy, or Mounjaro?
For most UK users considering GLP-1 treatment in 2026, the practical ranking is:
- Mounjaro (tirzepatide): generally most effective, weekly dosing, often first choice
- Wegovy (semaglutide): effective, weekly dosing, strong cardiovascular data, second-line alternative
- Saxenda (liraglutide): modest efficacy, daily dosing, third-line for specific clinical contexts
Saxenda as a first-line choice in 2026 is unusual unless there are specific clinical reasons (tolerance issues with other medications, pregnancy-related considerations, specific cardiovascular context).
Wegovy and Mounjaro are the practical choices for most private UK prescribing.
Specific scenarios
Scenario 1: Type 2 diabetes + weight loss goals. Mounjaro often wins — strong glycaemic control + significant weight loss. Ozempic (semaglutide equivalent) is a close second. Saxenda rarely chosen here.
Scenario 2: Cardiovascular disease history. Wegovy has the strongest cardiovascular benefit data. Mounjaro is accumulating evidence but Wegovy is currently the more validated choice for cardiovascular protection.
Scenario 3: Couldn’t tolerate Mounjaro. Wegovy is the next reasonable choice — different pharmacokinetic profile, sometimes tolerated better. Saxenda third choice.
Scenario 4: Supply issues with weekly medications. Saxenda (daily liraglutide) may be more reliably available at certain UK suppliers during tirzepatide/semaglutide shortages. Temporary switch can bridge supply gaps.
Scenario 5: First-line for general weight management. Wegovy or Mounjaro both appropriate. Choice depends on provider availability, price, and personal preference. Saxenda rarely chosen.
The summary
Wegovy (weekly semaglutide) is generally more effective and more convenient than Saxenda (daily liraglutide), making it the preferred choice for most UK adults needing a GLP-1 alternative to Mounjaro. Saxenda remains a valid option in specific clinical contexts (tolerance issues, supply gaps, specific pathways) but is rarely first-line in 2026. For most users, the practical choice is between Mounjaro and Wegovy, with Saxenda as a backup.
For broader GLP-1 context: Tirzepatide vs Semaglutide UK, Ozempic vs Wegovy UK, and the Complete GLP-1 Weight Loss Guide.
Medical note: this is general information about medication comparisons. Choosing between GLP-1 options requires consideration of your specific medical history, current medications, cardiovascular risk, and personal circumstances. Always discuss with a qualified prescriber.
Discover more from Healthy Weight Loss GLP1
Subscribe to get the latest posts sent to your email.
